Frequency Therapeutics Stock Performance
| KRRO Stock | 52.31 1.69 3.34% |
On a scale of 0 to 100, Frequency Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 3.87, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Frequency Therapeutics will likely underperform. Please check Frequency Therapeutics' jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to make a quick decision on whether Frequency Therapeutics' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Frequency Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting basic indicators, Frequency Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.34 | Five Day Return 4.91 | Year To Date Return 6.45 | Ten Year Return (92.36) | All Time Return (92.36) |
Last Split Factor 1:50 | Last Split Date 2023-11-06 |
1 | Insider Trading | 08/30/2024 |
2 | Acquisition by Cerio Jeffrey of 40000 shares of Frequency Therapeutics at 44.37 subject to Rule 16b-3 | 09/03/2024 |
3 | 3 Stocks That Could Rise on European Bank Interest Rate Cuts | 09/27/2024 |
4 | Wall Street Analysts Think Korro Bio, Inc. Could Surge 239.54 percent Read This Before Placing a Bet | 10/16/2024 |
5 | Disposition of tradable shares by Agarwal Vineet of Frequency Therapeutics at 82.89 subject to Rule 16b-3 | 10/17/2024 |
6 | Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board | 11/04/2024 |
7 | Disposition of 800 shares by Agarwal Vineet of Frequency Therapeutics at 70.0 subject to Rule 16b-3 | 11/11/2024 |
8 | Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/12/2024 |
9 | Korro Bio Sees Large Volume Increase Following Better-Than-Expected Earnings | 11/13/2024 |
10 | Korro Bio Given Outperform Rating at William Blair | 11/14/2024 |
11 | Korro Bio Earns Buy Rating from HC Wainwright | 11/15/2024 |
12 | Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 12a Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency | 11/21/2024 |
13 | Korro Bio Given Buy Rating at HC Wainwright | 11/22/2024 |
| Begin Period Cash Flow | 41.5 M |
Frequency |
Frequency Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,970 in Frequency Therapeutics on August 27, 2024 and sell it today you would earn a total of 261.00 from holding Frequency Therapeutics or generate 5.25% return on investment over 90 days. Frequency Therapeutics is currently generating 0.6276% in daily expected returns and assumes 12.7204% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Frequency, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Frequency Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Frequency Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Frequency Therapeutics, and traders can use it to determine the average amount a Frequency Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0493
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KRRO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Frequency Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Frequency Therapeutics by adding it to a well-diversified portfolio.
Frequency Therapeutics Fundamentals Growth
Frequency Stock prices reflect investors' perceptions of the future prospects and financial health of Frequency Therapeutics, and Frequency Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Frequency Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 394.84 M | ||||
| Shares Outstanding | 9.37 M | ||||
| Price To Book | 2.73 X | ||||
| EBITDA | (80.9 M) | ||||
| Net Income | (81.17 M) | ||||
| Total Debt | 33.21 M | ||||
| Book Value Per Share | 19.28 X | ||||
| Cash Flow From Operations | (67.28 M) | ||||
| Earnings Per Share | (9.42) X | ||||
| Market Capitalization | 490.05 M | ||||
| Total Asset | 221.66 M | ||||
| Retained Earnings | (183 M) | ||||
| Working Capital | 153.25 M | ||||
About Frequency Therapeutics Performance
By examining Frequency Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Frequency Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Frequency Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (12.32) | (12.93) | |
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.48) | (0.45) |
Things to note about Frequency Therapeutics performance evaluation
Checking the ongoing alerts about Frequency Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Frequency Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Frequency Therapeutics is way too risky over 90 days horizon | |
| Frequency Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (81.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Frequency Therapeutics generates negative cash flow from operations | |
| Frequency Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Korro Bio Given Buy Rating at HC Wainwright |
- Analyzing Frequency Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Frequency Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Frequency Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Frequency Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Frequency Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Frequency Therapeutics' stock. These opinions can provide insight into Frequency Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Frequency Therapeutics. If investors know Frequency will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Frequency Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.42) | Return On Assets (0.35) | Return On Equity (0.75) |
The market value of Frequency Therapeutics is measured differently than its book value, which is the value of Frequency that is recorded on the company's balance sheet. Investors also form their own opinion of Frequency Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Frequency Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Frequency Therapeutics' market value can be influenced by many factors that don't directly affect Frequency Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Frequency Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Frequency Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Frequency Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.